Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$288.84
Open:$288.69
Day's Low:$284.71
Day's High:$291.32
Bid / Ask:-
Market Cap:505.40B
Enterprise Value:574.78B
52-Week Range
52-Week Low:$190.75
52-Week High:$298.74
Current position in 52-week range
52w Low-52w High
50-Day Avg:$269.77
200-Day Avg:$237.46
Volume
Volume Today:5,348,839
Avg Volume (3m):4,741,120
Avg Volume (10d):5,132,190
52-Week Change:+33.79%
vs S&P 500, 52 weeks:-
Beta:0.19
Valuation Multiples
P/E (trailing):49.23
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 3, 2026. The P/E is the price divided by that EPS.
P/E (forward):17.67
PEG Ratio:0.59
Price / Book:-
Price / Sales (TTM):7.66
EV / Revenue:8.71
EV / EBITDA:18.13
Dividends
Current yield:2.40%
Annual Dividend Rate:$6.92
Dividend Trailing:$6.92
Yield Trailing:2.40%
5-Year Avg Yield:3.41%
Payout Ratio:190.40%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):66.01B
Gross Profit:48.67B
EBITDA:31.71B
Net Income (TTM):10.30B
Rev Growth (YoY):+10.30%
Earnings Growth (YoY):+2,282.10%
Quarterly earnings growth (YoY):+2,167.70%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$5.81
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 3, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$16.18
Revenue Per Share:$37.32
Cash Per Share:-
Book Value:$-3.36
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:6.57B
Total Debt:70.88B
Net Debt (Debt - Cash):64.32B
Debt / Equity:-
Current Ratio:-
Quick Ratio:-
Cash Flows
Operating Cash Flow:-
Free Cash Flow (FCF):-
FCF Yield (FCF / Market Cap):-
Enterprise Value:574.78B
EV / Revenue:8.71
EV / EBITDA:18.13
Profitability
ROE (Return on Equity):-
ROA (Return on Assets):-
P/E (trailing):49.23
P/E (forward):17.67
Price / Book:-
PEG Ratio:0.59
52-Week Change:+33.79%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$5.81
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 3, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$16.18
P/E (forward):17.67
PEG Ratio:0.59
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$37.32
Cash Per Share:-
Book Value:$-3.36
Cash Flows (TTM)
Free Cash Flow:-
Operating Cash Flow:-
EBITDA:31.71B
Total Revenue (TTM):66.01B
Net Income (TTM):10.30B
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:1,767,117,285
Float (free shares):1,763,971,816
Short interest (shares):15,582,821
Short % of float:-
Short Ratio (days to cover):3.22
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
AbbVie Inc. (ABBV) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Executive VP of Research & Development and Chief Scientific Officer
53
3.56M
Mr. Jeffrey Ryan Stewart
Executive VP & Chief Commercial Officer
56
5.00M
Ms. Linda Ray
Senior VP & Chief Information Officer
-
-
Ms. Elizabeth Shea
Senior Vice President of Investor Relations
-
-
Mr. Perry C. Siatis
Executive VP, General Counsel & Secretary
50
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
AbbVie Inc. (ABBV): Quantitative Analysis
AbbVie Inc. (ABBV) — Healthcare — Drug Manufacturers - General. ABBV is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, ABBV has returned +28.2% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
ABBV ranks 72 of 461 on today's multifactor score, and 6 of the 55 Healthcare companies that score. Its strongest factor is growth (Z 0.71, ranked 51 of 489); its weakest is value (Z -0.60, ranked 421 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
AbbVie has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Oct 30, 2026). ABBV earnings dates and times, quarter by quarter →
What is AbbVie's P/E ratio?
AbbVie's P/E (price over earnings per share for the last twelve months) is 49.2 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: AbbVie is above its sector median. Healthcare stocks, company by company →
Where does AbbVie rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, AbbVie ranks 72 of 461, and 6 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have AbbVie insiders bought or sold shares?
SEC Form 4 shows no open-market purchase of AbbVie shares from August 2025 through Nov 3, 2026. The latest sale was on Aug 14, 2026, by an officer, for $8.2M. In total, from August 2025 through Nov 3, 2026: 0 purchases and 4 sales by directors, officers and large shareholders. All ABBV insider trades →
Does AbbVie pay a dividend?
Yes. Its dividend yield is 2.40% at the Nov 3, 2026 close (annual dividend of $6.92 per share). The next announced ex-dividend date is Jan 15, 2027.
What sector is AbbVie in, and which index?
AbbVie is classified in the Healthcare sector (industry: Drug Manufacturers - General), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.